Published Standard Number 1 – Applications (National)

| Application number | Application type | Number of applications | Performance | Target days |
|--------------------|--|------------------------|-------------|----------------|
| 1 | Complex timetable | 3 | 100% | 210.0 |
| | (National new MA applications) Complex new MA applications, e.g. | | | |
| | novel therapies, new actives | | | |
| 2 | Major timetable | 1 | 100% | 180.0 |
| | (National) New MRLs. All other MA | | | |
| | applications (excl. MAPI and | | | |
| 0 | Copycats) | 4.4 | 4000/ | 400.0 |
| 3 | Standard timetable (National Type II variations. New | 41 | 100% | 120.0 |
| | MA - MAPIs and Copycats. New | | | |
| | VHRs) | | | |
| 4 | Shortened timetable | 163 | 100% | 60.0 |
| | (National Renewals (MA and VHR) | | | |
| | Type IB variations. New ATC (type | | | |
| E | B). Out of Scope MRLs) Minor timetable | 448 | 97.5% | 20.0 |
| 5 | (National) Type IA variations. | 448 | 97.5% | 30.0 |
| | Administrative Type IB variations. | | | |
| | New ATC (Type A/S). ATC | | | |
| | variations and renewals. | | | |
| 6 | Parallel Assessment with EU | 155 | 100% | - |
| - | Procedures | 0 | | |
| 7 | Shared Assessment with International Partners | 0 | - | - |
| 8 | Batch timetable | 33 | 100% | 20.0 |
| O | (National) specific Batch Control | 33 | 100 /0 | 20.0 |
| 9 | Autogenous Vaccines. New & | 0 | 0 | 45.0 |
| | Variations | | | |

Published Standard Number 1 – Applications (Other)

| Application number | Application Type | Number of applications | Performance |
|--------------------|--|------------------------|-------------|
| 10 | Mock-up period completed within 20 days (or up to 40 days for parallel applications involving different QRD sources) | 166 | 95.8% |
| 11 | Validation | 468 | 95.9% |
| 12 | Issue of authorised documentation | 805 | 90.8% |

Published Standard Number 1 – Applications (European - NI)

| Application number | Application Type | Number of applications | Performance |
|--------------------|--|------------------------|-------------|
| 13 | New Decentralised (DCP) | 9 | 100% |
| 14 | New Mutual Recognition (MRP) | 3 | 100% |
| 15 | MRP Variations (Type IB & II) and Renewals | 100 | 100% |

Published Standard Number 2 – Public Assessment Reports

| Application number | Application type | Total number | Performance |
|--------------------|--|--------------|-------------|
| 16 | Publishing Summary of Product Characteristics (SPCs) | 10 | 100% |
| 17 | Publishing Public Assessment Reports (PuARs) | 17 | 100% |
| 18 | Ùpdating PuARs | 1 | 100% |

Published Standard Number 3 – Quality of Documentation

| Applicatio | n number | Application type | Number of applications | Performance |
|------------|-----------|------------------|------------------------|-------------|
| 19 | Unreturne | d Documents | 1125 | 98.6% |

Published Standard Number 4 – Product Defects

| Task | Task | Number of tasks | Performance |
|--------|-------------------------|-----------------|-------------|
| number | | | |
| 20 | Product Defects reports | 19 | 100% |
| | High risk <5 days | 1 | - |
| | Low risk <10 days | 18 | - |

Published Standard Number 5 - Import, Export and Batch Release Schemes

| Application number | Application Type | No of Apps | Performance | Target Days |
|--------------------|---|---------------|-------------|----------------|
| 21 | Applications for new products | 32 | 100% | 15/25 |
| 22 | Applications for previously imported products | 78 | 100% | 15 |
| 23 | All other urgent applications | 66 | 100.0% | - |
| | Urgent | 0 | | 2 |
| | Non Urgent | 66 | | 10 |
| 24 | Instant Import Certificates | 10,080 | - | - |
| 25 | Export | 95 | 100% | 10 |
| 26 | Batch Release | 607 | 100% | 10 |

Published Standard Number 6 - Pharmacovigilance

| Task number | Task | No. | Performance |
|----------------|------------------------------------|------|-------------|
| 27 | Human, Animal & Environmental AERs | 2097 | 87.3% |
| 28 | PSURs | 478 | 100% |
| 29 | Inspections | 5 | 100% |

Published Standard Number 7– Inspections

| Task number | Task | No. | Performance | Target Days |
|----------------|--|-----|------------------|----------------|
| 30 | Inspections within 3 years (GMP) | 11 | 100% | - |
| | Within 5 years (GDP) of last inspection | 4 | Joint with above | - |
| 31 | Inspection Deficiency Reports | 19 | 100% | 30.0 |
| 32 | (GMP) Certificates or (GDP) final reports sent | 6 | 100% | 90.0 |
| 33 | Approval of new Feed business operators and SQP retailer sites | 20 | 100% | 45.0 |
| 34 | Final inspection report to Feed business operators and SQP retailers | 135 | 100% | 30.0 |

Our inspection procedures enable us to extend our GMP inspections beyond 3 years and our GDP inspections beyond 5 years where there are exceptional circumstances, provided a documented risk-assessment is carried out. Risk-assessments have been conducted for all sites where it has not been possible for us to inspect them within 3 years due to covid-19 related restrictions, which were in place until March 2022.

Published Standard Number 8 - Enforcement

| Task number | Task | No. | Performance |
|----------------|------------------------|-----|-------------|
| 35 | Quarterly VMR Breaches | 1 | 100% |
| 36 | Intelligence Activity | 12 | 100% |

Published Standard Number 9 - Residues

| Task number | Task | No. | Performance |
|----------------|----------------------------------|------|-------------|
| 37 | Quarterly Non-Compliance Data | 0 | 0 |
| 38 | Sample Testing | 8449 | 98.7% |
| 39 | Residue Violation Investigations | 12 | 41.8% |

Key:

100% Excellent

>97% - 100% Excellent, but some targets missed

92% - 97% Effective

< 91% Ineffective

Additional information

The VMD continuously monitors all targets and puts in place countermeasures, where possible, to ensure targets are met.

However, sometimes a performance standard may fall into the effective or ineffective category and there are a number of reasons why this may happen, for example high volume of applications, staff resource, complexity of applications requiring additional input and so on.